Research Topics
| Eugenia NegredoSummaryAffiliation: Lluita contra la SIDA Foundation Country: Spain Publications
| Collaborators
|
Detail Information
Publications
Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statinsEugenia Negredo
Lluita contra la SIDA, Germans Trias i Pujol Hospital, Universitat Autonoma de Barcelona, Ctra de Canyet s n, 08916 Badalona, Barcelona, Spain
AIDS 20:2159-64. 2006..To assess the efficacy, safety, and pharmacokinetic interactions of ezetimibe in HIV-infected patients with poorly controlled antiretroviral-associated dyslipidaemia while taking pravastatin alone...- Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA)Eugenia Negredo
Lluita contra la SIDA Foundation, Barcelona, Spain
Clin Infect Dis 49:892-900. 2009..This study aimed to evaluate in vivo the effects of NRTI withdrawal on mitochondrial parameters and body fat distribution... - Benefits and concerns of simplification strategies in HIV-infected patientsEugenia Negredo
Lluita contra la SIDA Foundation, HIV Unit, Universitat Autonoma de Barcelona, Hospital Universitari Germans Trias i Pujol Barcelona, Spain
J Antimicrob Chemother 58:235-42. 2006..An accurate analysis of each patient's history will be necessary in each case to determine whether a simplification strategy is appropriate... - Four-year safety with polyacrylamide hydrogel to correct antiretroviral-related facial lipoatrophyEugenia Negredo
Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
AIDS Res Hum Retroviruses 25:451-5. 2009..However, prolonged follow-up of these patients is recommended to detect unexpected long-term adverse reactions... - Nadir CD4 T cell count as predictor and high CD4 T cell intrinsic apoptosis as final mechanism of poor CD4 T cell recovery in virologically suppressed HIV-infected patients: clinical implicationsEugenia Negredo
Lluita contra Sida Foundation, Institut de Recerca en Ciències de Salut Germans Trias i Pujol, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, Barcelona, Spain
Clin Infect Dis 50:1300-8. 2010..Although antiretroviral therapy improves immune response, some human immunodeficiency virus-infected patients present unsatisfactory CD4 T cell recovery despite achieving viral suppression, resulting in increased morbidity and mortality... - Partial immunological and mitochondrial recovery after reducing didanosine doses in patients on didanosine and tenofovir-based regimensEugenia Negredo
Germans Trias i Pujol University Hospital, Lluita contra la SIDA and IrsiCaixa Foundations, University of Barcelona, 08916 Badalona, Barcelona, Spain
Antivir Ther 13:231-40. 2008..We assessed whether a simple reduction of the ddl dose in patients receiving ddl (400 mg/day) and TDF could revert this side effect... - Treatment simplification to once daily darunavir/ritonavir guided by the darunavir inhibitory quotient in heavily pretreated HIV-infected patientsJose Molto
Lluita contra Sida Foundation, HIV Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
Antivir Ther 15:219-25. 2010..We explored a treatment simplification strategy to darunavir/ritonavir 900/100 mg once daily guided by the darunavir virtual inhibitory quotient (vIQ) in patients receiving salvage therapy with darunavir/ritonavir 600/100 mg twice daily... - Increased antiretroviral potency by the addition of enfuvirtide to a four-drug regimen in antiretroviral-naive, HIV-infected patientsJose Molto
Lluita contra la SIDA Foundation, HIV Unit, Germans Trias i Pujol Hospital, Badalona, Spain
Antivir Ther 11:47-51. 2006..To assess if enfuvirtide (ENF) increases antiviral activity of a highly active four-drug antiretroviral (ARV) regimen containing lopinavir/ritonavir, efavirenz, lamivudine and tenofovir in ARV-naive, HIV-infected patients... - Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approachEugenia Negredo
Lluita contra la SIDA Foundation, Germans Trias i Pujol Hospital, Badalona, Spain
Antivir Ther 9:335-42. 2004..To assess the efficacy and safety of a once-daily antiretroviral regimen in HAART-experienced subjects with long-lasting viral suppression... - Lopinavir/ritonavir plus nevirapine as a nucleoside-sparing approach in antiretroviral-experienced patients (NEKA study)Eugenia Negredo
Department of Internal Medicine, Lluita contra la SIDA and IrsiCaixa Foundations, Germans Trias i Pujol Hospital, Badalona, Universitat Autonoma de Barcelona, Barcelona, Spain
J Acquir Immune Defic Syndr 38:47-52. 2005..To compare the efficacy and safety of a nucleoside-sparing approach with a conventional highly active antiretroviral therapy (HAART) regimen in antiretroviral-experienced patients with prolonged viral suppression... - Effect of nevirapine on the steady-state trough concentrations of atazanavir in HIV-infected patients receiving atazanavir/ritonavirJose Molto
Lluita contra la SIDA Foundation, HIV Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
Ther Drug Monit 32:93-6. 2010..Atazanavir Ctroughs were compared between Days 0 and 28. Atazanavir and nevirapine Ctroughs at Day 28 were compared with historical controls receiving either 400 mg atazanavir once daily or 200 mg nevirapine twice daily... - Interruptions of antiretroviral therapy in human immunodeficiency virus infection: are they detrimental to neurocognitive functioning?Jose A Muñoz-Moreno
Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Badalona, Barcelona, Catalonia, Spain
J Neurovirol 16:208-18. 2010..Additionally, neurocognitive functioning was observed to be more impaired in the same individuals. Further studies should examine the potential negative effects of antiretroviral therapy interruptions on neurocognitive functioning... - Efficacy and safety of ritonavir dose reduction based on the tipranavir inhibitory quotient in HIV-infected patients on salvage antiretroviral therapy with tipranavir/ritonavirJose Molto
Lluita contra la SIDA Foundation, HIV Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
AIDS Res Hum Retroviruses 26:1191-6. 2010.... - High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort studyAnna Bonjoch
Lluita contra la SIDA Foundation, University Hospital Germans Trias, Barcelona, Spain
AIDS 24:2827-33. 2010..Low bone mineral density (BMD) is an emerging metabolic condition in HIV-infected patients; however, data on progression of this disease are scarce... - Mild improvement in mitochondrial function after a 3-year antiretroviral treatment interruption despite persistent impairment of mitochondrial DNA contentEugenia Negredo
Lluita contra la SIDA Foundation, Germans Trias i Pujol Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
Curr HIV Res 8:379-85. 2010..The ability of a prolonged antiretroviral treatment interruption to reverse mitochondrial toxicity was evaluated in a sub-study of TIBET, a prospective trial examining antiretroviral treatment interruption guided by CD4+ cell count... - Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practiceJose Molto
Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
Ther Drug Monit 29:648-51. 2007..Therapeutic drug monitoring may be useful in this setting... - Association between HIV replication and cholesterol in peripheral blood mononuclear cells in HIV-infected patients interrupting HAARTEugenia Negredo
Lluita contra la SIDA Foundation, Institut de Recerca en Ciències de la Salut Germans Trias i Pujol, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, 08916 Badalona, Barcelona, Spain
J Antimicrob Chemother 61:400-4. 2008..Cellular cholesterol is essential for HIV replication and may control HIV spread. HIV, in turn, appears to control cholesterol metabolism... - Simultaneous population pharmacokinetic model for lopinavir and ritonavir in HIV-infected adultsJose Molto
Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
Clin Pharmacokinet 47:681-92. 2008..It is coformulated with low doses of ritonavir in order to enhance its pharmacokinetic profile. After oral administration, plasma concentrations of lopinavir can vary widely between different HIV-infected patients... - Lopinavir/ritonavir monotherapy as a simplification strategy in routine clinical practiceJose Molto
Lluita contra la SIDA Foundation, Germans Trias i Pujol Hospital, Badalona, and Universidad Autonoma de Barcelona, Spain
J Antimicrob Chemother 60:436-9. 2007..The objective of this study was to assess the effectiveness and safety of monotherapy with lopinavir/ritonavir as a treatment simplification strategy in HIV-infected patients with viral suppression outside a clinical trial setting... - Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherenceCarmina R Fumaz
Lluita contra la SIDA Foundation, HIV Unit Germans Trias i Pujol Hospital, Autonomous University of Barcelona, Barcelona, Spain
J Acquir Immune Defic Syndr 38:560-5. 2005..Efavirenz has been associated with neuropsychiatric disorders, although little is known about its long-term toxicity... - Alternation of antiretroviral drug regimens for HIV infection. Efficacy, safety and tolerability at week 96 of the Swatch StudyEugenia Negredo
Department of Internal Medicine, Lluita contra la SIDA and IrsiCaixa Foundations, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain
Antivir Ther 9:889-93. 2004..Alternation of antiretroviral drug regimens has been proposed as a novel treatment strategy for HIV infection. However, some concerns persist regarding antiviral efficacy, adherence, toxicity and resistance evolution in the long term... - Role of structured treatment interruption before a 5-drug salvage antiretroviral regimen: the Retrogene StudyLidia Ruiz
Retrovirology Laboratory, IrsiCaixa Foundation and Lluita contra la SIDA Foundation, Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona, Barcelona, Spain
J Infect Dis 188:977-85. 2003..66; 95% confidence interval, 0.47-0.93; P=.021). A prior STI seems to confer no additional benefit to subsequent virological or immunological outcomes of a salvage regimen... - Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimensCarmina R Fumaz
HIV Unit, Fundació Lluita SIDA and IrsiCaixa Retrovirology Laboratory, Germans Trias i Pujol University Hospital, Badalona, Catalonia, Spain
J Acquir Immune Defic Syndr 29:244-53. 2002.... - Low levels of adherence to antiretroviral therapy in HIV-1-infected women with menstrual disordersCarmina R Fumaz
Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Badalona, Barcelona, Spain
AIDS Patient Care STDS 23:463-8. 2009..The subjective attribution of these irregularities to antiretrovirals seems to affect medication intake, possibly favoring negative clinical consequences... - Genetic and functional mitochondrial assessment of HIV-infected patients developing HAART-related hyperlactatemiaGloria Garrabou
Mitochondrial Research Laboratory, Internal Medicine Department, Hospital Clinic of Barcelona, IDIBAPS, University of Barcelona and CIBER de Enfermedades Raras, CIBERER, Barcelona, Spain
J Acquir Immune Defic Syndr 52:443-51. 2009.... - Influence of prior structured treatment interruptions on the length of time without antiretroviral treatment in chronically HIV-infected subjectsJose Molto
HIV Clinical Unit Lluita Contra Ia Sida Foundation, Hospital Universitari Germans Trias i Pujol, 08916 Badalona, Barcelona, Spain
AIDS Res Hum Retroviruses 20:1283-8. 2004..Previous STIs do not influence time off therapy when HAART is definitively discontinued in chronically HIV-infected subjects. CD4 nadir is an important factor in the treatment discontinuation decision... - Reconstructive treatment for antiretroviral-associated facial lipoatrophy: a prospective study comparing autologous fat and synthetic substancesEugenia Negredo
HIV Unit, Fundació de la Lluita contra la SIDA, Germans Trias i Pujol University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
AIDS Patient Care STDS 20:829-37. 2006..Similar results were observed for all degrees of severity and between genders. Polyacrylamide gel provided the longest lasting benefits... - Impact of switching from lopinavir/ritonavir to atazanavir/ritonavir on body fat redistribution in virologically suppressed HIV-infected adultsElena Ferrer
HIV Unit, Service of Infectious Diseases, Hospital Universitari de Bellvitge, L Hospitalet de Llobregat, Barcelona, Spain
AIDS Res Hum Retroviruses 27:1061-5. 2011..008) and subcutaneous fat (42%, p = 0.008). These data suggest that switching from LPV/r to ATV/r is associated with increased trunk fat, both subcutaneous and visceral... - Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovirMaria Saumoy
Infectious Disease Service, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain
Antivir Ther 16:459-68. 2011.... - Herb-drug interaction between Echinacea purpurea and darunavir-ritonavir in HIV-infected patientsJose Molto
Lluita contra la SIDA Foundation, HIV Clinic, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
Antimicrob Agents Chemother 55:326-30. 2011..Although no dose adjustment is required, monitoring darunavir concentrations on an individual basis may give reassurance in this setting... - Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates, and management. A neurobehavioral reviewJose A Muñoz-Moreno
Lluita Contra la SIDA Foundation Germans Trias i Pujol University Hospital, Badalona, Barcelona, Spain
AIDS Rev 11:103-9. 2009..Different recommendations on the assessment of efavirenz-related adverse events are also provided... - Saquinavir exposure in HIV-infected patients with chronic viral hepatitisJose Molto
Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
J Antimicrob Chemother 63:992-7. 2009.... - Viral failure in HIV-infected patients with long-lasting viral suppression who discontinued enfuvirtideAnna Bonjoch
Lluita contra la SIDA Foundation, AIDS Care Unit, Hospital Universitari Germans Trias i Pujol, , Badalona, Spain
AIDS 20:1896-8. 2006..5%) and in no patients, respectively, (P = 0.007). The CD4 cell decrease in failure patients was 5% (P = ns). These results suggest that enfuvirtide should be maintained until new active drugs became available... - Saquinavir/ritonavir monotherapy as a new nucleoside-sparing maintenance strategy in long-term virologically suppressed HIV-infected patientsEcheverria Patricia
Germans Trias i Pujol University Hospital, Barcelona, Spain
Curr HIV Res 8:467-70. 2010..The high antiviral potency and low toxicity of saquinavir/ritonavir (SQV/r) prompted us to assess a viable strategy in chronic virologically suppressed HIV-infected patients... - Once- or twice-daily dosing of nevirapine in HIV-infected adults: a population pharmacokinetics approachJose Molto
Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
J Antimicrob Chemother 62:784-92. 2008.... - Nadir CD4 cell count predicts neurocognitive impairment in HIV-infected patientsJose A Muñoz-Moreno
Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Badalona, Barcelona, Catalonia, Spain
AIDS Res Hum Retroviruses 24:1301-7. 2008..We found differences in neurocognitive functioning in relation to nadir CD4 count in HIV-infected patients. Attention should be given to this value in the management of neurocognitive protection in HIV infection... - Lopinavir/ritonavir pharmacokinetics in HIV and hepatitis C virus co-infected patients without liver function impairment: influence of liver fibrosisJose Molto
Fundació Lluita contra la Sida, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
Clin Pharmacokinet 46:85-92. 2007..To assess the influence of hepatitis C virus (HCV) co-infection and the extent of liver fibrosis on lopinavir/ritonavir pharmacokinetics in HIV-infected patients without liver function impairment... - Evaluation of the anti-HIV activity of statinsGemma Moncunill
Retrovirology Laboratory IrsiCaixa and HIV Unit, Hospital Universitari Germans Trias i Pujol, , 08916 Badalona, Spain
AIDS 19:1697-700. 2005..No anti-HIV activity was detected at subtoxic concentrations and simvastatin did not induce a significant change in the mean viral load or CD4 cell count in study patients. We caution on the use of statins as antiretroviral agents... - HIV-1 infection in subjects older than 70: a multicenter cross-sectional assessment in Catalonia, SpainBeatriz Mothe
Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Catalonia, Spain
Curr HIV Res 7:597-600. 2009..Based on our findings, we suggest some recommendations regarding the management of this growing population... - Assessing self-reported adherence to HIV therapy by questionnaire: the SERAD (Self-Reported Adherence) StudyJose A Muñoz-Moreno
Lluita contra la SIDA Foundation, Badalona, Barcelona, Catalonia, Spain
AIDS Res Hum Retroviruses 23:1166-75. 2007.... - Alternation of antiretroviral drug regimens for HIV infection. A randomized, controlled trialJavier Martinez-Picado
IrsiCaixa Foundation, Hospital Germans Trias i Pujol, Carretera de Canyet s n, 08916 Badalona, Spain
Ann Intern Med 139:81-9. 2003..Mathematical modeling has suggested that alternating antiretroviral regimens while patients' viral load remains suppressed would minimize HIV resistance mutations... - Validation of estimated renal function measurements compared with the isotopic glomerular filtration rate in an HIV-infected cohortAnna Bonjoch
University Hospital Germans Trias, Barcelona, Spain
Antiviral Res 88:347-54. 2010.... - The changing face of HIV/AIDS in treated patientsJosep M Llibre
Lluita contra la SIDA Foundation, University Hospital Germans Trias, Barcelona 08916, Spain
Curr HIV Res 7:365-77. 2009..The present review focuses on these twelve areas of increasing interest for physicians currently facing successfully treated HIV+ patients... - Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapineEugenia Negredo
Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, , Badalona, Spain
AIDS 16:1383-9. 2002..These changes are expected to reduce the risk of cardiovascular disease in HIV-1-infected patients on highly active antiretroviral therapy... - Safety of Switching Nevirapine Twice Daily to Nevirapine Once Daily in Virologically Suppressed PatientsDaniel Podzamczer
Hospital Universitari de Bellvitge, L Hospitalet, Barcelona, Spain
J Acquir Immune Defic Syndr 50:390-6. 2009..The strategy of switching nevirapine (NVP) twice daily to once daily was evaluated... - CD4 T-cell hyperactivation and susceptibility to cell death determine poor CD4 T-cell recovery during suppressive HAARTMarta Massanella
Fundació irsiCaixa HIVACAT, Institut de Recerca en Ciències de la Salut Germans Trias i Pujol IGTP, Hospital Germans Trias, Universitat Autonoma de Barcelona, Spain
AIDS 24:959-68. 2010..However, the relative contribution of these factors is still unclear, strongly limiting the definition of appropriate therapeutic strategies for these patients... - Reversal of HIV-1-associated osteoporosis with once-weekly alendronateEugenia Negredo
Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Badalona, Barcelona, Spain
AIDS 19:343-5. 2005..Improvements in trochanter BMD were obtained after 2 years. Once-weekly oral alendronate may be an effective and safe treatment for HIV-1-associated osteoporosis... - Impact of nevirapine on lipid metabolismBonaventura Clotet
Germans Trias i Pujol University Hospital, Barcelona, Spain
J Acquir Immune Defic Syndr 34:S79-84. 2003..These favorable lipid profiles may be of clinical benefit in reducing the risk for coronary artery disease in HIV-1 infected patients who are receiving long-term antiretroviral therapy... - HIV protease inhibitors and dyslipidemiaBonaventura Clotet
HIV Unit and Retrovirology Laboratory, IrsiCaixa Foundation, Hospital Universitari, Germans Trias i Pujol, Carretera del Canyet s n Badalona, Barcelona, Spain
AIDS Rev 5:19-24. 2003..The need for lipid reduction therapy may be minimized with the use of new PIs that are comparable in efficacy to current PIs but do not negatively affect lipid levels... - [Contribution of human papillomavirus second-generation hybrid capture test for the diagnosis of cervical pathology in HIV-infected outpatients]Guillem Sirera
Unidad VIH, Servicio de Medicina, Hospital Universitario Germans Trias i Pujol, Universitat Autonoma de Barcelona, Ctra de Canyet s n, 08916 Badalona, Barcelona, Spain
Med Clin (Barc) 125:127-31. 2005.... - Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppressionEugenia Negredo
Fundació Lluita contra la Sida, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain
Clin Infect Dis 34:504-10. 2002..Quality of life significantly improved for groups A and B. In patients receiving effective PI-based therapy, the replacement of the PI with either nevirapine or efavirenz is safe and virologically effective...